https://scholars.lib.ntu.edu.tw/handle/123456789/518152
標題: | Switching biologics in psoriasis - practical guidance and evidence to support | 作者: | Tsai Y.-C. TSEN-FANG TSAI |
關鍵字: | Biologic; Il-12; Il-17; Il-23; inadequate response; psoriasis; switch; TNF-alpha | 公開日期: | 2020 | 出版社: | Taylor and Francis Ltd | 卷: | 13 | 期: | 5 | 起(迄)頁: | 493-503 | 來源出版物: | Expert Review of Clinical Pharmacology | 摘要: | Introduction: Advances of biologic agents have changed the treatment paradigm of psoriasis to higher efficacy and better quality of life. However, the demand for biologic switch is increasing due to patient’s greater expectation and decreasing efficacy in long-term use. Also, biologic-induced adverse effects necessitate the switching of biologics. Areas covered: This review article was divided into two parts. The first part focused on the biologic switch due to lack of efficacy. The second part provided switching suggestions related to adverse effects. Expert commentary: Biologic switch in psoriasis was mainly due to lack of efficacy, and the subsequent biologic agent was usually given at the next scheduled time point without washout period. In pivotal randomized controlled trials, patients with poor response to TNF-alpha inhibitors and ustekinumab achieved better efficacy after switching to IL-23 and IL-17 inhibitors. In addition, real-world data showed that intra-class switch could still achieve a 50%-80% of PASI 75 response in individuals with anti-IL-17 failure histories. As for the biologic switch due to adverse effects, washout period was recommended and transition to a biologic agent with different modes of action was preferred, especially class-specific adverse events. ? 2020, ? 2020 Informa UK Limited, trading as Taylor & Francis Group. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85086160197&doi=10.1080%2f17512433.2020.1767590&partnerID=40&md5=b2192bb6ccfd89230ee56dd6ca4d186a https://scholars.lib.ntu.edu.tw/handle/123456789/518152 |
ISSN: | 1751-2433 | DOI: | 10.1080/17512433.2020.1767590 | SDG/關鍵字: | adalimumab; biological product; brodalumab; etanercept; guselkumab; interleukin 17; interleukin 23; ixekizumab; risankizumab; secukinumab; tildrakizumab; tumor necrosis factor inhibitor; ustekinumab; biological product; dermatological agent; adverse drug reaction; alopecia areata; drug efficacy; drug safety; drug substitution; hepatitis B; hepatitis C; human; multiple sclerosis; psoriasis; Review; treatment response; psoriasis; quality of life; randomized controlled trial (topic); Biological Products; Dermatologic Agents; Drug Substitution; Humans; Psoriasis; Quality of Life; Randomized Controlled Trials as Topic |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。